Viraj Kiran Lavingia
Viraj Kiran Lavingia publishes mostly in Oncology, Pathology and Forensic Medicine and Cancer Research, on topics such as Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer and Cancer Genomics and Diagnostics.
- World rank
- #4,971,079 of 7,710,434 ranked researchers
- Rank in India
- #135,695 of 280,097
- Works
- 35
- Citations
- 191
- Citations per work
- 5.5
What does Viraj Kiran Lavingia research?
Viraj Kiran Lavingia's work is mostly in Medicine (72%), Biochemistry, Genetics and Molecular Biology (12%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences2572.1%
- Medicine2572.1%
- Everything else515.5%
- Life Sciences412.4%
- 1Oncology34% of their works
- 2Pathology and Forensic Medicine13% of their works
- 3Cancer Research12% of their works
- 4Surgery11% of their works
- 5Pulmonary and Respiratory Medicine11% of their works
- 6Radiology, Nuclear Medicine and Imaging2% of their works
Research topics
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Screening and Detection
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Surgical Treatments
Which keywords describe Viraj Kiran Lavingia's research?
The keywords of their largest research topics: Chemotherapy, Adjuvant Chemotherapy, Cetuximab, KRAS Mutations, Microsatellite Instability, Molecular Characterization, Cancer Genomics and Mutational Signatures.
- Rectal Cancer
- PD-1 and PD-L1
- Surgical Complications
- Pancreatic Cancer
- Tumor Microenvironment
- Cholangiocarcinoma
- Mutational Signatures
- Molecular Characterization
- KRAS Mutations
- Adjuvant Chemotherapy
- Chemotherapy
- Cetuximab
- Microsatellite Instability
- Cancer Genomics
- Biliary Tract Cancer
- Neoadjuvant Therapy
- Colorectal Cancer
- Screening
- Immune Checkpoint Blockade
- Preoperative Chemoradiotherapy
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 20 words, with their numbers
- Chemotherapy162 topics
- Adjuvant Chemotherapy142 topics
- Cetuximab121 topic
- KRAS Mutations121 topic
- Microsatellite Instability121 topic
- Molecular Characterization121 topic
- Cancer Genomics111 topic
- Mutational Signatures111 topic
- Biliary Tract Cancer61 topic
- Cholangiocarcinoma61 topic
- Neoadjuvant Therapy62 topics
- Tumor Microenvironment62 topics
- Colorectal Cancer41 topic
- Pancreatic Cancer41 topic
- Screening41 topic
- Surgical Complications41 topic
- Immune Checkpoint Blockade21 topic
- PD-1 and PD-L121 topic
- Preoperative Chemoradiotherapy21 topic
- Rectal Cancer21 topic
Where does Viraj Kiran Lavingia work?
Viraj Kiran Lavingia's main affiliation in the publication record is Shalby Hospitals, India.
How many publications and citations does Viraj Kiran Lavingia have?
OpenAlex counts 35 works and 191 citations for Viraj Kiran Lavingia, an h-index of 4, ranking #4,971,079 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Viraj Kiran Lavingia. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.